(Reuters) – China’s CanSino Biologics Inc said on Wednesday that no serious blood clot cases related to its COVID-19 vaccine had been reported so far.
The announcement comes amid multiple cases of people being diagnosed with a blood clot after receiving COVID-19 shots made by AstraZeneca and Johnson & Johnson.
(Reporting by Shashwat Awasthi in Bengaluru; Editing by Shounak Dasgupta)